More news articles

Lilly starts world first trial of an antibody drug for COVID-19

Drug is the first to be specifically designed to treat the virus

Pfizer’s Ibrance misses the mark in early breast cancer

Drug was unable to demonstrate statistical significance in primary endpoint

ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer

PD-1 inhibitor more than doubled progression-free survival compared to chemotherapy

ASCO: Bavencio boosts survival post-chemo in bladder cancer

Merck KGaA and Pfizer report drug reduces risk of death by 31%

IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine

CEOs of vaccine giants AZ, GSK, J&J and Pfizer pledge to pull out all the stops

Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir

The 450-patient phase 3 trial combines an antiviral with an immune modulator

GSK plans to produces one billion doses of vaccine adjuvant for COVID-19

Company will support numerous vaccine candidates

UK government launches NHS test and trace service

New service initiated as part of national recovery strategy and aims to test and trace every suspected case of coronavirus in the country

EMA clears BMS’ oral multiple sclerosis drug Zeposia

EvaluatePharma estimates drug could earn $1.6bn in 2024

Gilead shells out $375m for immuno-oncology deal with Arcus

Wide-ranging deal gives company access to bulk of biotech’s immuno-oncology pipeline

UK clears NHS use of Gilead’s remdesivir for COVID-19 patients

MHRA approved the drug under the Early Access to Medicines Scheme

Merck buys Themis as part of drive for COVID-19 drugs and vaccines

Deal also adds a pipeline of vaccines for other infectious diseases as well as cancer

FDA backs BMS’ Opdivo/Yervoy in first-line NSCLC

Finally wins approval in market dominated by rival Keytruda

New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell

Remdesivir could speed recovery of patients with COVID-19, but hydroxychloroquine may not be safe

CEPI-backed coronavirus vaccine from Novavax starts trials

NVX-CoV2373 is tenth vaccine to reach human testing stage

NICE approves Roche’s Tecentriq in TNBC after revising deal

Discounted price deal sees immunotherapy recommended for use